Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ASND, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Lonapegsomatropin FDA approved Aug 2021 · Skytrofa |
Achondroplasia | Phase 3 · NCT07924059 | Not yet recruiting |
| Navepegritide FDA approved Feb 2026 · Yuviwel |
Hypochondroplasia | Phase 3 · NCT07917143 | Not yet recruiting |
| Palopegteriparatide FDA approved Aug 2024 · Yorvipath |
Hypoparathyroidism | N/A · NCT05654701 | Approved for marketing |
| TransCon hGH | Growth Hormone Deficiency, Pediatric | Phase 3 · NCT03344458 | Completed |
| TransCon CNP | Achondroplasia | Phase 2/3 · NCT05929807 | Enrolling by invitation |
| Once daily subcutaneous injection of Genotropin | Growth Hormone Deficiency, Pediatric | Phase 3 · NCT02781727 | Completed |
| Once weekly subcutaneous injection of TransCon… | Growth Hormone Deficiency, Pediatric | Phase 3 · NCT02781727 | Completed |
| Trastuzumab Emtansine | Advanced Solid Tumor | Phase 1/2 · NCT05081609 | Active not recruiting |
| ACP-001 | Growth Hormone Deficiency (GHD) | Phase 2 · NCT01947907 | Completed |
| Resiquimod Hydrogel-based Sustained-release… | Advanced Solid Tumor | Phase 1/2 · NCT05081609 | Active not recruiting |
| Combination of Navepegritide and… | Achondroplasia | Phase 2 · NCT06433557 | Active not recruiting |
| Chemotherapy drug | Advanced Solid Tumor | Phase 1/2 · NCT05081609 | Active not recruiting |
| TransCon Treprostinil | Healthy Volunteers | Phase 1 · NCT03803163 | Terminated |
Also used in these trials (approved or third-party drugs, not ASND's own candidates): Somatropin, Trastuzumab, TransCon IL-2 β/γ, Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ASND holds $964.4M in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ASND files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc | Institution (13G, 5%+) | 8,194,812 | 13.22% | 2026-09-30 |
| Westfield Capital Management Company, L. | Institution (13G, 5%+) | 5,185,696 | 8.37% | 2025-12-31 |
| JANUS HENDERSON GROUP PLC | Institution (13G, 5%+) | 3,719,452 | 6.00% | 2026-03-31 |
| FMR LLC | Institution (13G, 5%+) | 3,425,993 | 5.53% | 2026-09-30 |
| Jan Moller Mikkelsen Director |
Insider | 453,403 | 0.73% | 2026-03-18 |
| Kennett Sprogoe EVP & Head of Research & Product Develop |
Insider | 19,570 | 0.03% | 2026-03-18 |
| Pedersen Anni Lotte Kirstine Sonderbjerg EVP & Chief Admin Officer |
Insider | 19,460 | 0.03% | 2026-03-18 |
| Scott Thomas Smith EVP & Chief Financial Officer |
Insider | 4,367 | 0.01% | 2026-06-02 |
| Lars Holtug Director |
Insider | 4,000 | 0.01% | 2026-09-02 |
| Albert Cha Director |
Insider | 3,730 | 0.01% | 2026-03-18 |
| Jean Jacques Bienaime Director · +9,160 options |
Insider | 2,900 | 0.00% | 2026-08-14 |
| Siham Imani Director |
Insider | 2,317 | 0.00% | 2026-03-18 |
Share count 61,977,408 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ASND and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →